MIRA
INFORM REPORT
|
Report Date : |
23.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
PARS DAROU CO. |
|
|
|
|
Registered Office : |
Eastern 144 St, Tehranpars 1st Sq.Tehran 1654713691 |
|
|
|
|
Country : |
Iran |
|
|
|
|
Date of Incorporation : |
1960 |
|
|
|
|
Com. Reg. No.: |
7546 |
|
|
|
|
Legal Form : |
Public Joint Stock Company |
|
|
|
|
Line of Business : |
Pharmaceutical preparations for the cardiovascular system, central and
autonomic nervous system |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Company
Details
Company Name: Pars Darou Co.
Headquarter
Address: Eastern 144 St,
Tehranpars 1st Sq.
Tehran 1654713691
Iran
P. O. Box: 11365 4688
Tel: +98 21 77704061
+98 21 77704062
+98
21 77704063
+98 2177704064
+98 21 77704065
+98 21 77704066
+98 21 77704067
Fax: +98 21 77877701
+98 2177877700
Website: www.parsdarou.ir
E-mail: parsdarou@parsdarou.ir
History
In 1960, Bayer Germany, established the 1st subsidiary
of trans-national pharmaceutical company in Iran, named "Bayer Pharma
Iran"(BPI) from 1981 "BPI"renamed to PARS DAROU and re-oriented
to generics. With more than 40 years experience in the fled of pharmaceutical
production and after receiving ISO 9001,2000 & OHSAS 18001:1999 & ISO
14001:1996 moving towards the implementation of total quality management
(T.Q.M)is one of the future objectives of the company.
Share holding: shares offered in Tehran stock exchange since 1995 currently
with over 14000 shareholders.
Registration
& Legal Details
Current Legal Form: Public Joint Stock Company
Registration Address: Eastern 144
St.,Tehran Pars 1st Sq.
Tehran 16546
Iran
Registration Number: 7546
Registration Date: 1960
Year Established: 1960
Registration Town: Tehran
Capital
Currency: Iranian Rials
Nominal capital: 70,000,000,000
|
Number of Shares: 70,000,000 |
Type of Shares: None Selected |
|
Issued Shares: - |
Value per share: IRI 1,000.00 |
Shareholders
|
Shareholder Names/ Address |
% of Voting/Non-Voting Capital |
|
Social Security Investment
Tehran Iran |
%26 |
|
Saba Taamin
Investment Company Tehran Iran |
%21 |
|
Taamin
Pharmaceutical Investment Company Tehran Iran |
%10 |
|
Others Iran |
%20 |
|
Pharmaceutical
Investment Company Tehran Iran |
%23 |
Principals
Name: Mr. Ataollah Nafei
Position within the company: Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi- English
Name: Mr. Khalil Rajati
Position within the company: Member
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mr. Mohamad Taghi Darabi
Position within the company: Managing Director
Country of Birth:
Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mr. Mehdi Shadnoosh
Position within the company: Member
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mr. Shahrokh Amir Samimi
Position within the company: Vice Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi- English
Company
Activities
Production of finished dosage forms:
Pharmaceutical preparations for the cardiovascular system, central and
autonomic nervous system
Pharmaceutical preparations for metabolism, nutrition, alimentary
systems. Pharmaceutical preparations for urology, dermatology, gynaecology and
obstetrics
Chemotherapeutic agents, endocrines,
antiseptics, immunological preparations
Local Reporters consider the investigated company to be
Large their field of concern.
Operations
Employees
Company Employs:
500
HQ Premises
Operates from: Owned Offices, Warehouses,
Factory
Location: Central Business Area, Main Road
Imports
Imports: Raw Material
Import%: 20%
Import from: China, Italy, India, Germany, UK, Netherlands
Hungary, Spine
Import terms: letters of credit
Additional: balance of 80% purchased via
local market
Export
Exports: Finished Goods
Export%: 25%
Export from: Africa, Pakistan, CIS, Afghanistan
Export terms: letters of credit
Trading
& Selling
Territory: 75% Nationality,
25 % Internationally
Type of Customer: General Public, Local
Authorities
Terms of sales: Cash, letters of credit
Vehicles: Total number of vehicles: 95
Related
Companies
Subsidiaries:
Farabi pharmaceutical company P.J.S. Co
Tehran
Iran.
Pars Darou is the founder and major shareholder ( about 60 percent) of this
immense oral semi synthetic Penicillins production company in Isfahan province
.
Affiliates:
Hejrat distribution P.J.S. Co
Tehran
Iran.
Pars Darou owns 18.8 percent of the shares.
Amin pharmaceutical P.J.S. Co.
Isfahan
Iran .
Pars Darou is holding shares equal to 16%, in a joint - venture with a group of
other Iranian pharmaceutical companies .
Banks
Bank Saderat
Tehran
Iran
Bank Tejarat
Tehran
Iran
Bank Melli
Tehran
Iran
Financial
Information
Source: Ms. Behnoosh Jafari (Secretary)
Currency: Iranian Rials -
000,000
|
Months |
Date |
Sales |
Gross
|
Net |
|
12 |
29/03/2007 |
1065470 |
218000 |
162000 |
|
12 |
29/03/2006 |
924380 |
189000 |
146000 |
|
12 |
29/03/2005 |
823400 |
168000 |
131000 |
BALANCE SHEET
Source: Financial Estimates on
29/03/2006
Currency: Iranian Rials
Note: Figures in 000,000
|
NEW WORTH |
164000 |
|
Trade Creditor |
90000 |
|
Total Liabilities |
122000 |
|
|
|
|
Trade Debtors |
79000 |
|
Total Assets |
297000 |
Payments
Subject's payments reported to be: NO COMPLAINTS
interview
& reporter comments
Name/Title: Ms. Behnoosh Jafari (Secretary)
In the interview conducted with Ms. Behnoosh Jafari (Secretary), She
declined bank account numbers citing the grounds of Company
confidentiality.
Conclusion
Local Reputation: The company being investigated is considered by local reporters to be a
Normal Trade Risk.
General Conclusion:
Local informants consider granting of credit to be a fair trade risk.
Owner/Shareholders Comments:
Some of owners involved in the running of
the business
Age of Business: Old
Business
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)